| Balance Sheets | 2025-06-30 | |||
|---|---|---|---|---|
| Property and equipment, net | 36,617 | |||
| Short-term restricted cash | 0 | |||
| Prepaid expenses and other current assets | 10,240 | |||
| Income tax receivable | 24 | |||
| Cash and cash equivalents | 44,812 | |||
| Short-term marketable securities | 159,299 | |||
| Accounts receivable | 8,333 | |||
| Total current assets | 222,708 | |||
| Long-term restricted cash | 3,360 | |||
| Other long-term assets | 94 | |||
| Operating lease, right-of-use assets | 38,250 | |||
| Total assets | 301,029 | |||
| Accrued expenses and other current liabilities | 10,853 | |||
| Operating lease liabilities | 2,394 | |||
| Liability related to the sale of future royalties | 27,755 | |||
| Accounts payable | 3,547 | |||
| Total current liabilities | 44,549 | |||
| Other long-term liabilities | 252 | |||
| Operating lease liabilities, net of current portion | 55,656 | |||
| Series 1 nonconvertible preferred stock | 1,350 | |||
| Liability related to the sale of future royalties, net of current portion | 119,943 | |||
| Total liabilities | 221,750 | |||
| Accumulated deficit | -386,229 | |||
| Common stock 0.01 par value per share, 100,000 shares authorized 21,378 and 21,194 shares issued and outstanding at june 30, 2025 and september 30, 2024, respectively | 214 | |||
| Additional paid-in capital | 465,696 | |||
| Accumulated other comprehensive (loss) gain | -402 | |||
| Total stockholders' equity | 79,279 | |||
| Total liabilities and stockholders' equity | 301,029 | |||
ENANTA PHARMACEUTICALS INC (ENTA)
ENANTA PHARMACEUTICALS INC (ENTA)